Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma
Author:
Affiliation:
1. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Publisher
Informa UK Limited
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2215922
Reference31 articles.
1. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
2. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
3. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
4. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
5. Inhibitory Receptors Beyond T Cell Exhaustion
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Correction;Expert Opinion on Biological Therapy;2024-08-08
2. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody;Scientific Reports;2024-05-09
3. Pathology and Molecular Biology of Melanoma;Current Issues in Molecular Biology;2023-06-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3